Beactica

1 known investors

Beactica Therapeutic uses targeted protein degradation (TPD) technology, including its Eclipsor™ platform, to develop precision therapeutics for disease targets previously considered undruggable. The company focuses on advancing novel therapeutic candidates toward clinical development.